Given the deficiency of agonist and antagonist of DJ-1, a better understanding of the interaction between DJ-1 and ischemia postconditioning protection could only be achieved by simple-linear regression; thus, further silencing and overexpression of DJ-1 via genetic engineering would be needed, which could add to a further comprehension of the underlying mechanism and may provide a promising alternative in the prevention and treatment of cardiovascular disease with DM. Here, PARK7 is linked to cardiovascular disorder.